Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $60.73 Consensus Target Price from Analysts
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […]
